RE:Breast cancer treatment: perspectives on the oncolytic virus
Will oncolytic viruses potentially replace or complement monoclonal antibodies (‘mabs’) like Bevacizumab in the future?
Oncolytic viruses have the potential to complement monoclonal antibodies (mAbs) like Bevacizumab in the future. Oncolytic viruses are a novel regimen in cancer therapy that can mediate antitumor effects by infecting cancer cells and presenting tumor-associated antigens to the immune system, boosting immunological activity in the tumor microenvironment [1]. They can be genetically engineered to enhance their selectivity and effectiveness, and clinical studies are investigating their efficacy in combination with various anti-cancer therapeutics, including mAbs [2] [3]. Additionally, oncolytic viruses can be engineered to express therapeutic antibodies, allowing for the delivery of antibodies to tumors and complementing viral oncolysis with antibody-defined therapeutic action [4]. This strategy has shown promising results in terms of direct tumor cell killing, anti-angiogenesis, and activation of adaptive immune responses [5]. Therefore, oncolytic viruses have the potential to work synergistically with mAbs and improve patient outcomes in cancer therapy.
https://typeset.io/questions/will-oncolytic-viruses-potentially-replace-or-complement-398dpptghu